PGR and neoplasm: There is a large degree of overlap between the immunohistochemical subtypes defined by ER, PR and HER2 status, and those identified by molecular expression studies, including with Ki67 expression (a marker of tumor cell proliferation) used additionally to distinguish between the luminal subtypes [18].